News & Updates

Among individuals with type 2 diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) does not contribute to increased pancreatic cancer risk, according to a study.

A voice-based conversational artificial intelligence application helps type 2 diabetes (T2D) patients navigate basal insulin titration at home and, in turn, achieve rapid glycaemic control, as reported in a study.

Use of semaglutide 2.4 mg results in substantial weight reduction in patients with severe obesity who had previously undergone bariatric surgery (BS) but failed to achieve satisfactory weight loss, reports a recent study.

A recent study has shown that healthy men and women with overweight or obesity who undergo voluntary calorie restriction (CR), without a structure exercise program, attain decreases in skeletal muscle (SM) mass of approximately 2 to 2.5 kg and 1 to 1.5 kg per 10-kg weight loss, respectively.

Semaglutide is associated with a 49─73 percent lower risk of suicidal ideation vs other agents for treatment of obesity and type 2 diabetes mellitus (T2DM), a National Institutes of Health (NIH)─funded study has shown.